ENVERIC BIOSCIENCES, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
ENVERIC BIOSCIENCES, INC. (ENVB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $3.07 per share for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-26.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2024-03-26
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2016-03-31 was $6.02.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $3.07, a 97.94% decline from fiscal 2021.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $149.00, a 15751.06% increase from fiscal 2020.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $0.94, a 52.76% decline from fiscal 2019.
- ENVERIC BIOSCIENCES, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2019 was $1.99.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $3.07 10-K · filed 2024-03-26 | ||||
| 2021-12-31 | $149.00 10-K/A · filed 2023-06-09 | $2.98 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $3.50 10-Q · filed 2021-11-15 | ||||
| 2020-12-31 | $0.94 10-K · filed 2022-03-31 | ||||
| 2019-12-31 | $1.99 10-K · filed 2021-04-01 | ||||
| 2016-12-31 | $6.79 10-K/A · filed 2017-04-04 | ||||
| 2016-09-30 | $6.79 10-Q · filed 2016-11-14 | ||||
| 2016-06-30 | $6.86 10-Q · filed 2016-08-12 | ||||
| 2016-03-31 | $6.02 10-Q · filed 2016-05-16 | ||||
| 2015-12-31 | $2.67 10-KT · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |